ABVC BioPharma Q2 2024 EPS improves 86.8% to -$0.09; licensing deals worth up to $292M

ABVC BIOPHARMA, INC.

2024-Q2 EPS reported -$0.47 revenue$118,347

EPS improved 86.8% YoY to -$0.09 in Q2 2024 from -$0.68; revenue surged to $117,142 from $6,109.
Executed global licensing agreements for Vitargus (up to $187M) and oncology products (up to $105M) totaling potential $292M.
Received $116,000 cash milestone in June 2024 from Vitargus licensing.
Shareholders' equity stood at $7.8M as of June 30, 2024.
Obtained US, Taiwanese, and Australian patents for Polygala extract for MDD and ADHD; FDA approved four INDs for oncology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.